• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 12, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Bowel cancer medication could help combat early-onset Parkinson’s disease

Bioengineer by Bioengineer
March 14, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

People with certain forms of early-onset Parkinson's disease could potentially benefit from taking a medication used to treat certain forms of cancer, according to new research by University of Leicester scientists and funded by the Medical Research Council.

The study, which has been published in Science Matters, suggests that folinic acid, which is used in medications to treat bowel cancer, can also protect neurons associated with Parkinson's disease in fruit flies.

Dr Miguel Martins from the MRC Toxicology Unit at the University of Leicester explained: "Parkinson's disease is a disabling disorder for which no cure is yet available; further, after dopaminergic neurons are lost, only a few palliative treatment options for Parkinson's symptoms are available. Therefore, treatments that either prevent or delay the onset of the disease at an early stage are needed.

"Folinic acid is already approved and used for applications in the clinic as an adjuvant during chemotherapy and can be administered orally, as a dietary supplement, or intravenously.

"Thus, the drug safety risk is low, and drug development for repurposing folinic acid as a treatment for Parkinson's disease would be faster than for a novel drug.

"With this in mind, it seems worthwhile to further test the supplementation of folinic acid in clinical trials with human participants as a potential preventative or palliative therapeutic for PD and to expand the repertoire of treatment options."

The researchers studied fruit flies with faulty mitochondria caused by a mutation that mimics Parkinson's disease in humans. Lab experiments, like this, allow us to draw conclusions about the effect of folinic acid on neurons in fruit flies.

Previous research by the team has shown that folic acid protects neurons in models of Parkinson's disease. Folinic acid is related to folic acid but is metabolically more active.

In contrast to folic acid, folinic acid taken orally can penetrate into the human brain.

###

The paper, 'Folinic acid is neuroprotective in a fly model of Parkinson's disease associated with pink1 mutations', published in Science Matters, is available here: https://sciencematters.io/articles/201702000009

Images of the research team and fruit flies are available here: https://www.dropbox.com/sh/l0uknlo02pnko3w/AAD7lGwiNDHqswS7v0j54sSNa?dl=0

Media Contact

Dr Miguel Martins
[email protected]
@UoLNewsCentre

http://www.leicester.ac.uk

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

High-Performance Microchannels for Electronic Cooling Solutions

High-Performance Microchannels for Electronic Cooling Solutions

October 12, 2025

Exploring NHS Staff Retention Policies: Current Gaps

October 12, 2025

Ultrasound-Activated Nanovesicles Transform Metabolic Processes

October 12, 2025

Aptamer-Enhanced Monocytes Reduce Tau and Neuroinflammation

October 12, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1223 shares
    Share 488 Tweet 305
  • New Study Reveals the Science Behind Exercise and Weight Loss

    103 shares
    Share 41 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    100 shares
    Share 40 Tweet 25
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    89 shares
    Share 36 Tweet 22

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

High-Performance Microchannels for Electronic Cooling Solutions

Exploring NHS Staff Retention Policies: Current Gaps

Ultrasound-Activated Nanovesicles Transform Metabolic Processes

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 64 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.